CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.

[1]  S. Gottschalk,et al.  T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies , 2016, Scientific Reports.

[2]  H. Heslop,et al.  Antigen-specific T cell therapies for cancer. , 2015, Human molecular genetics.

[3]  R. Handgretinger,et al.  NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML , 2015, Journal of immunology research.

[4]  P. Moore,et al.  A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates , 2015, Science Translational Medicine.

[5]  R. Walter,et al.  Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia , 2015, Current Hematologic Malignancy Reports.

[6]  Michel Sadelain,et al.  New cell sources for T cell engineering and adoptive immunotherapy. , 2015, Cell stem cell.

[7]  J. Heiber,et al.  Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia , 2015, Haematologica.

[8]  M. Carroll,et al.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia , 2015, Leukemia.

[9]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[11]  Feng Yu,et al.  Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  Quan-shun Wang,et al.  Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[14]  S. Grupp,et al.  Engineered T cells for cancer therapy , 2014, Cancer Immunology, Immunotherapy.

[15]  B. Savoldo,et al.  Erratum: Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study (Blood (2013) 122:17 (2965-2973)) , 2014 .

[16]  M. Carroll,et al.  Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. , 2014, Blood.

[17]  L. Hoffman,et al.  Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications , 2014, Front. Oncol..

[18]  D. Bonnet,et al.  Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo , 2014, Leukemia.

[19]  S. Rosenberg,et al.  Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.

[20]  U. Testa,et al.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.

[21]  Sadik H. Kassim,et al.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.

[22]  L. Naldini,et al.  CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. , 2013, Blood.

[23]  A. Scott,et al.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Xiuli Wang,et al.  T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. , 2013, Blood.

[25]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[26]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[27]  R. Grossman,et al.  T cells redirected to EphA2 for the immunotherapy of glioblastoma. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Angel F. Lopez,et al.  Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD123‐specific chimeric antigen receptor , 2013, British journal of haematology.

[29]  F. Nestle,et al.  Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype , 2012, PloS one.

[30]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[31]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[32]  M. Loh,et al.  Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study , 2010, Pediatric blood & cancer.

[33]  A. Scott,et al.  Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen , 2010, Gene Therapy.

[34]  M. Kester,et al.  Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy , 2009, Haematologica.

[35]  D. Greiner,et al.  Human peripheral blood leucocyte non‐obese diabetic‐severe combined immunodeficiency interleukin‐2 receptor gamma chain gene mouse model of xenogeneic graft‐versus‐host‐like disease and the role of host major histocompatibility complex , 2009, Clinical and experimental immunology.

[36]  Casey Weaver,et al.  Noninvasive bioluminescence imaging in small animals. , 2008, ILAR journal.

[37]  Mitchell Ho,et al.  New Immunotoxins Targeting CD123, a Stem Cell Antigen on Acute Myeloid Leukemia Cells , 2007, Journal of immunotherapy.

[38]  A. Bernad,et al.  Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA × anti-CD3 diabodies from lentivirally transduced human lymphocytes , 2007, Cancer Gene Therapy.

[39]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[40]  W. Woods.  Curing childhood acute myeloid leukemia (AML) at the half‐way point: Promises to keep and miles to go before we sleep , 2006, Pediatric blood & cancer.

[41]  T. Lister,et al.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.

[42]  D. Fremont,et al.  Costimulation through NKG2D Enhances Murine CD8+ CTL Function: Similarities and Differences between NKG2D and CD28 Costimulation1 , 2005, The Journal of Immunology.

[43]  G. Mufti,et al.  IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  M. Serafini,et al.  Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. , 2004, Human gene therapy.

[45]  Irving L. Weissman,et al.  Prospective isolation of human clonogenic common myeloid progenitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Aventín,et al.  Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. , 2001, Haematologica.

[47]  T. Barbui,et al.  Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. , 2000, Human gene therapy.

[48]  J. Downing,et al.  Acute myeloid leukemia. , 1999, The New England journal of medicine.

[49]  J. Gamble,et al.  IL‐3 receptor expression, regulation and function in cells of the Vasculature. , 1996, Immunology and cell biology.

[50]  D. Greiner,et al.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.

[51]  J. Weinstein,et al.  Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. , 1987, Cancer research.